医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment

2019年09月17日 PM10:15
このエントリーをはてなブックマークに追加


 

TAIPEI, Taiwan

There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devices suppliers.

Cancer treatment is one of medical specialties that Taiwan gains recognition in Asia. The focal point now goes to proton therapy, which is proven to be a painless way to deliver radiation dose in targeted tumours precisely and maintains side effects happening in the minimum level.

Proton therapy key players race for Asia markets

Despite proton therapy indicating a promising alternative for cancer treatments, it is far from close to a mainstream service that can be found in medical institutes. As per PTCOG statistics, there are 82 medical institutes to date having the therapy on offer, with one in operation and 9 to go in Taiwan- the highest density as opposed to the rest of the world. Chang Gung Memorial Hospital launched the service in 2015, followed closely by its peers including Taipei Medical University Hospital, China Medical University Hospital, Taipei Veterans General Hospital, National Taiwan University Hospital and 5 more known domestically and regionally, aiming at increasing demands by patients in ASEAN nations.

Multinational medical device tycoons, too, leap at opportunities they see in Taiwan by forming allies to medical centres, namely IBA, Varian, Hitachi and SHI Group. Their presence suggests that Taiwan is well positioned with its medical expertise and geographic location for being a demo site where business would develop from, it also approves Taiwan’s capacity for driving innovation and application of cancer treatment.

Taiwan excels at treating cancers in head, neck and breast areas, and tumours found in children

Proton therapy combining with other treatments is found useful for lung cancer and tumours in head and neck areas. Taiwan-based medical institutes have been propelling positive results through clinical cases and research, noting that breast cancer and cancers developed in children can be a critical addition to strengthen Taiwan’s strategic foothold in Asia, together with engineering and science specialists involved in course of treatment.

Multinational manufacturers of radiation therapy (including proton) equipment and their hospital partners will feature live demonstration and techniques behind advanced cancer treatment on 5-8 December 2019, at the Healthcare+ Expo Taiwan.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190917005041/en/

CONTACT

Healthcare+ Expo Taiwan

Silvia Fan

+886 2 2655 7888 Ext.649

silvia@rbmp.org.tw

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease